MG ODQ 1PC x 10MG

Biochem/physiol Actions

Target IC₅₀: 20 nM against nitric oxide (NO)-sensitive guanylyl cyclase

Reversible: yes

Product does not compete with ATP.

Cell permeable: yes

Primary Target(NO)-sensitive guanylyl cyclase

General description

A cell-permeable, potent and selective inhibitor of nitric oxide (NO)-sensitive guanylyl cyclase (IC₅₀ = 20 nM). In incubated cerebellum slices, ODQ reversibly inhibits the NO-dependent cGMP response to glutamate receptor agonists without affecting NOS activity. It does not chemically inactivate NO; however, it does inhibit cGMP generation in response to NO donors. ODQ does not inhibit NO-mediated macrophage toxicity, a phenomenon unrelated to cGMP, nor does it affect the activity of particulate guanylyl cyclase or adenylyl cyclase.

A potent and selective inhibitor of nitric oxide (NO)-sensitive guanylyl cyclase (IC₅₀ = 20 nM). In incubated cerebellum slices, ODQ reversibly inhibits the NO-dependent cGMP response to glutamate receptor agonists without affecting NOS activity. It does not chemically inactivate NO; however, it does inhibit cGMP generation in response to NO donors. ODQ fails to inhibit NO-mediated macrophage toxicity, a phenomenon unrelated to cGMP, nor does it affect the activity of particulate guanylyl cyclase or adenylyl cyclase.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Wang, D., et al. 1998. J. Biol. Chem. 273, 33027.Southam, E., et al. 1996. Br. J. Pharmacol. 119, 527.Brunner, F., et al. 1995. FEBS Lett.376, 262.Garthwaite, J., et al. 1995. Mol. Pharmacol.48, 184.

Packaging

10 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Irritant (B)